PCM
RAPT

Penserra Capital Management’s RAPT Therapeutics RAPT Stock Holding History

Penserra Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-84
Closed -$20K – 1512
2021
Q3 		$20K Buy
84
+13
+18% +$3.44K ﹤0.01% 1248
2021
Q2 		$18K Buy
71
+1
+1% +$187 ﹤0.01% 1173
2021
Q1 		$12K Sell
70
-1
-1% -$165 ﹤0.01% 1015
2020
Q4 		$11K Buy
+71
New +$15.4K ﹤0.01% 917

Other funds holding RAPT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Penserra Capital Management's RAPT Position: Q4 2021 in Review

Penserra Capital Management sold out of RAPT Therapeutics (RAPT) in Q4 2021, closing a stake of 84 shares — an estimated $20K sold.

Penserra Capital Management first reported a position in RAPT in Q4 2020 and held it in 4 quarters. The position peaked at $20K in Q3 2021. 99 funds tracked by Wall St. Rank hold RAPT as of Q4 2021.

  • Penserra Capital Management reported no remaining RAPT Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 84 RAPT Therapeutics shares in Q4 2021, an estimated $20K.
  • Penserra Capital Management first reported a position in RAPT Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's RAPT Therapeutics position peaked at $20K in Q3 2021.
  • 99 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.